Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EZN 2968

Next Previous
X
Search
Drug Profile

EZN 2968

Alternative Names: EZN-2968; RG 6061; RO-7070179; SPC-2968

Latest Information Update: 17 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santaris Pharma
  • Developer Enzon Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Antisense oligoribonucleotides
  • Mechanism of Action Gene silencing; Hypoxia-inducible factor 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Liver cancer; Lymphoma; Solid tumours

Most Recent Events

  • 17 Jan 2024 RG 6061 is still in phase I trials for Liver cancer, Lymphoma, Solid tumours in the US (Enzon Pharmaceuticals pipeline, January 2024)
  • 22 Jan 2018 Roche completes a phase I trial in liver cancer (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT02564614)
  • 07 Aug 2017 Discontinued - Phase-I for Lymphoma in USA (IV) (Roche pipeline, July 2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top